Multinational Non-Interventional Study (NIS) of Patients with ST- Segment Elevation Myocardial Infarction Treated with Primary Angioplasty and Concomitant Use of Upstream Antiplatelet Therapy with a Thienopyridine Agent
- Conditions
- MedDRA - Acute myocardial infarction. Code: 10000891I21Acute myocardial infarction
- Registration Number
- DRKS00003378
- Lead Sponsor
- Daiichi Sankyo Europe GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 2095
• At least 18 years of age / • Started antiplatelet therapy with a thienopyridine agent upstream based on an initial STEMI diagnosis before arrival at the cathlab hospital according to the authorization of the drug or standard of care. / • Transported to the cathlab (study centre) hospital by ambulance with the intention to perform primary angioplasty (patients can be picked-up from home or from a referring hospital) / • Written informed consent for participation in the NIS / • No current or planned enrolment in a clinical study. Exception: Patients with current or planned enrolment in a clinical study can be included if all of the following conditions are met: a) The patient’s treatment with thienopyridine antiplatelet drugs is not determined by the clinical study protocol but is performed according to the terms of authorization of the drug or standard of care - b) The patient’s actual treatment with antiplatelet drugs and anticoagulants is fully known (i.e. not blinded according to the clinical study protocol).
None
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br>Inhospital efficacy and safety of pre-treatment with Thienopyridines. Survival up to one year after Diagnosis. Analysis and comparision of transport times between sites and countries accross Europe.
- Secondary Outcome Measures
Name Time Method ot applicable